Abstract
Congenital Disorders of Glycosylation (CDG) are a rapidly growing family of genetic and mostly multisystem diseases caused by defects in the biosynthesis of the glycan moiety of glycoconjugates such as glycoproteins. Since the description of the first patients by Jaeken et al. in 1980, 23 defects have been identified in N- and O-protein glycosylation: 18 defects in N- or N- and O-glycosylation (12 glycan assembly defects: CDG-Ia to CDG-IL; 6 glycan processing defects: CDG-IIa to CDG-IIf) and 5 defects in O-glycosylation. There is a rapidly growing number of patients with a putative CDG in whom the known defects have been excluded (CDG-x). This review focuses on recent developments in the field including advances in the biochemical and molecular diagnosis of CDG and new features of known CDG. It also deals with the identification of new protein glycosylation disorders, of the first lipid glycosylation disorder, and of the emerging group of hyperglycosylation disorders. Finally, we speculate about future developments.
Keywords: CDG, COG, hyperglycosylation, lipid glycosylation, protein glycosylation
Current Pediatric Reviews
Title: Congenital Disorders of Glycosylation (CDG): Update and Perspectives
Volume: 2 Issue: 4
Author(s): Renate Zeevaert, Els Schollen, Hubert Carchon, Gert Matthijs and Jaak Jaeken
Affiliation:
Keywords: CDG, COG, hyperglycosylation, lipid glycosylation, protein glycosylation
Abstract: Congenital Disorders of Glycosylation (CDG) are a rapidly growing family of genetic and mostly multisystem diseases caused by defects in the biosynthesis of the glycan moiety of glycoconjugates such as glycoproteins. Since the description of the first patients by Jaeken et al. in 1980, 23 defects have been identified in N- and O-protein glycosylation: 18 defects in N- or N- and O-glycosylation (12 glycan assembly defects: CDG-Ia to CDG-IL; 6 glycan processing defects: CDG-IIa to CDG-IIf) and 5 defects in O-glycosylation. There is a rapidly growing number of patients with a putative CDG in whom the known defects have been excluded (CDG-x). This review focuses on recent developments in the field including advances in the biochemical and molecular diagnosis of CDG and new features of known CDG. It also deals with the identification of new protein glycosylation disorders, of the first lipid glycosylation disorder, and of the emerging group of hyperglycosylation disorders. Finally, we speculate about future developments.
Export Options
About this article
Cite this article as:
Zeevaert Renate, Schollen Els, Carchon Hubert, Matthijs Gert and Jaeken Jaak, Congenital Disorders of Glycosylation (CDG): Update and Perspectives, Current Pediatric Reviews 2006; 2 (4) . https://dx.doi.org/10.2174/157339606778699699
DOI https://dx.doi.org/10.2174/157339606778699699 |
Print ISSN 1573-3963 |
Publisher Name Bentham Science Publisher |
Online ISSN 1875-6336 |
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
Related Articles
-
Cardiac and Muscular Involvement in Idiopathic Inflammatory Myopathies: Noninvasive Diagnostic Assessment and the Role of Cardiovascular and Skeletal Magnetic Resonance Imaging
Inflammation & Allergy - Drug Targets (Discontinued) N-acetyl-seryl-aspartyl-lysyl-proline (Ac-SDKP): Potential target molecule in research of heart, kidney and brain
Current Pharmaceutical Design Cardiotoxicity of Molecularly Targeted Agents
Current Cardiology Reviews Emerging Potential of Natural Products as an Alternative Strategy to Pharmacological Agents Used Against Metabolic Disorders
Current Drug Metabolism Energy Remodeling, Mitochondrial Disorder and Heart Failure
Current Pharmaceutical Design Hypoxia and Fetal Heart Development
Current Molecular Medicine Mitochondrial Biogenesis in Health and Disease. Molecular and Therapeutic Approaches
Current Pharmaceutical Design The Role of Molecular Imaging in the Assessment of Cardiac Amyloidosis: State-of-the-Art
Current Radiopharmaceuticals Animal Modeling of Cancer Pathology and Studying Tumor Response to Therapy
Current Drug Targets Drug Therapy of Neuropathic Pain: Current Developments and Future Perspectives
Current Drug Targets The Role of Fibrate Treatment in Dyslipidemia: An Overview
Current Pharmaceutical Design Application of G-CSF in Congestive Heart Failure Treatment
Current Cardiology Reviews Cardiovascular Manifestations of COVID-19
Current Cardiology Reviews Genes Involved in Hereditary Hearing Impairment
Current Genomics Interrelationship Between Kidney Function and Percutaneous Mitral Valve Interventions: A Comprehensive Review
Current Cardiology Reviews Anti-infective and Antineoplastic Properties of Green Tea Catechins: Examining the Therapeutic Risk-benefit Ratio
Current Nutraceuticals Genetics and Gene Therapy of Anderson-Fabry Disease
Current Gene Therapy Cross Talk between the Cardiovascular and Nervous Systems:Neurotrophic Effects of Vascular Endothelial Growth Factor (VEGF) and Angiogenic Effects of Nerve Growth Factor (NGF)-Implications in Drug Development
Current Pharmaceutical Design Covid-19: Pathophysiology; Mechanism of Transmission and Possible Molecular Drug Target for Management
Current Molecular Pharmacology Dynamics of T Cells Repertoire During Trypanosoma cruzi Infection and its Post-Treatment Modulation
Current Medicinal Chemistry